SKYE / Skye Bioscience hires ophthalmic-focused CRO for Phase 2a US trial of glaucoma and hypertension treatment

Skye Bioscience Inc (OTCQB:SKYE) has entered into an agreement with Lexitas Pharma Services Inc, a full-service ophthalmic-focused contract research o more_horizontal

Skye Bioscience Inc (OTCQB:SKYE) said it has received a positive recommendation following a pre-specified data review by the safety review committee ( more_horizontal

Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND) more_horizontal

Skye Bioscience Inc (OTCQB:SKYE) said it has completed dosing of SBI-100 Ophthalmic Emulsion (OE) in the first cohort of healthy participants in the s more_horizontal

Skye Bioscience Inc (OTCQB:SKYE) said it has hired Dr Chris Twitty as the company's first chief scientific officer (CSO).  With over 25 years of life more_horizontal

San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company more_horizontal

Skye Bioscience Inc (OTCQB:SKYE) said it has started screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion (SBI-100 OE), a pr more_horizontal

Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted more_horizontal